Methods of treating Lennox-Gastaut Syndrome using fenfluramine
AssigneeZogenix International Limited
InventorsStephen J. Farr, Bradley S. Galer
Life of this patent
Estimating the term…
Abstract
A method of treating and/or preventing symptoms of Lennox-Gastaut Syndrome (LGS) also known as Lennox Syndrome in a patient such as a patient previously diagnosed with Lennox Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Lennox Syndrome patients are treated at a preferred dose of less than about 2.0 to about 0.01 mg/kg/day.
Claims20
A method of treating seizures associated with Lennox-Gastaut syndrome (LGS) in a patient suffering from LGS, comprising:
- administering an oral dose of fenfluramine or a pharmaceutically acceptable salt thereof to the patient in an amount in a range of 0.2 mg/kg/day to 0.8 mg/kg/day up to a maximum of 30 mg/day.
A method of treating seizures associated with Lennox-Gastaut syndrome (LGS) in a patient suffering from LGS, comprising:
- administering an oral solution of fenfluramine or a pharmaceutically acceptable salt thereof to the patient in an amount in a range of 0.2 mg/kg/day to 0.8 mg/kg/day up to a maximum of 30 mg/day;
- and
- administering a drug selected from the group consisting of stiripentol, clobazam, valproate and combinations thereof.
A method of treating seizures associated with Lennox-Gastaut syndrome (LGS) in a patient suffering from LGS, comprising:
- administering an oral dose of fenfluramine or a pharmaceutically acceptable salt thereof to the patient in an amount in a range of 0.2 mg/kg/day to 0.8 mg/kg/day up to a maximum of 30 mg/day;
- and
- administering a therapeutically effective amount of stiripentol to the patient.
Dependencies are inferred from the claim text.